Meiji Yasuda Asset Management Co Ltd. lessened its position in Merck & Company, Inc. (NYSE:MRK) by 1.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 107,185 shares of the company’s stock after selling 1,600 shares during the quarter. Merck & comprises 0.7% of Meiji Yasuda Asset Management Co Ltd.’s holdings, making the stock its 28th largest position. Meiji Yasuda Asset Management Co Ltd.’s holdings in Merck & were worth $6,869,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRK. Fort Washington Investment Advisors Inc. OH lifted its position in Merck & by 133.4% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 144,247 shares of the company’s stock worth $9,165,000 after buying an additional 82,454 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Merck & by 2.6% during the second quarter. Russell Investments Group Ltd. now owns 4,206,648 shares of the company’s stock worth $269,678,000 after buying an additional 107,201 shares in the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH lifted its position in Merck & by 41.9% during the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 296,294 shares of the company’s stock worth $19,028,000 after buying an additional 87,443 shares in the last quarter. Stevens Capital Management LP purchased a new position in Merck & during the first quarter worth approximately $15,126,000. Finally, Trust Co lifted its position in Merck & by 2.8% during the first quarter. Trust Co now owns 68,789 shares of the company’s stock worth $4,371,000 after buying an additional 1,852 shares in the last quarter. Institutional investors and hedge funds own 73.15% of the company’s stock.
A number of equities analysts recently commented on MRK shares. Cowen and Company reiterated a “hold” rating and set a $70.00 price objective on shares of Merck & in a research report on Friday, November 3rd. J P Morgan Chase & Co set a $70.00 target price on Merck & and gave the company a “buy” rating in a research report on Sunday, October 29th. Zacks Investment Research downgraded Merck & from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC restated a “sell” rating and issued a $55.00 target price on shares of Merck & in a research report on Friday, October 20th. Finally, Barclays PLC downgraded Merck & from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $72.00 to $62.00 in a research report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. Merck & has an average rating of “Hold” and an average target price of $67.07.
TRADEMARK VIOLATION NOTICE: This story was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/11/15/meiji-yasuda-asset-management-co-ltd-decreases-stake-in-merck-company-inc-mrk.html.
In related news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.25% of the company’s stock.
Merck & Company, Inc. (NYSE MRK) opened at $54.99 on Wednesday. Merck & Company, Inc. has a one year low of $54.41 and a one year high of $66.80. The company has a market capitalization of $150,116.47, a price-to-earnings ratio of 14.16, a P/E/G ratio of 2.37 and a beta of 0.78. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57.
Merck & (NYSE:MRK) last released its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. During the same period in the previous year, the firm posted $1.07 EPS. Merck &’s revenue for the quarter was down 2.0% on a year-over-year basis. analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.